Clinical trials: Glaucomatous Eyes
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Treatment With Either Beta-blockers or Prostaglandins Eye Drops
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00863811
- Where
- Italy
- Sponsor
- Sooft Italia
Glaucoma, Ocular Hypertension
Survey of Patients Taking IOP-Lowering Eye Drops
Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.
- Trial name
- NCT02384772
- Testing
- Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Open-Angle
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy.
- Trial name
- NCT00693485
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 2 sites in United States, Israel
- Volunteers
- 70 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.
- Trial name
- NCT03825380
- Testing
- Bimatoprost, Lumigan®
- Where
- Estonia
- Volunteers
- 485 people
- Sponsor
- Laboratoires Thea
Glaucoma
Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.
- Trial name
- NCT01156012
- Testing
- T2345, Prostaglandin
- Where
- France
- Volunteers
- 404 people
- Sponsor
- Laboratoires Thea
Glaucoma, Glaucoma, Open Angle
SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma
Study Objective: To establish the substantial equivalence of the SOLX Gold Shunt to commercially available aqueous shunts, specifically the Ahmed™ Glaucoma Valve Model FP7, in the ability to reduce intraocular pressure (IOP)…
- Trial name
- NCT00382395
- Testing
- SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 180 people
- Sponsor
- SOLX, Inc.
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Ocular Hypertension
IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients
The purpose of the study is to assess the relationship between IOP pattern as recorded over 24 hours by using Triggerfish and quantified by acrophase scored dichotomously, and conversion to glaucoma in OHT patients (conversion…
- Trial name
- NCT02030886
- Testing
- Sensimed Triggersfish® (TF)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sensimed AG
Glaucoma, Ocular Hypertension
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
The study purpose is to evaluate the safety of T4090.
- Trial name
- NCT05389267
- Testing
- Kinezodianone R hydrochloride
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Laboratoires Thea
Ocular Hypertension
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of…
- Trial name
- NCT03901781
- Testing
- ST266 via Intranasal Delivery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes
Maestro Agreement and Precision Study II
Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.
- Conditions
- Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
- Trial name
- NCT02376868
- Testing
- 3D OCT-1 Maestro, iVue
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Ocular Hypertension Glaucoma
Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.
To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in terms of efficacy.
- Trial name
- NCT04898387
- Testing
- Bimatoprost Timolol (T4030), Bimatoprost Timolol (Ganfort)
- Where
- Bulgaria
- Volunteers
- 554 people
- Sponsor
- Laboratoires Thea
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous patients initially treated, stabilised by…
- Trial name
- NCT02278614
- Testing
- T2347, Xalacom
- Where
- France
- Volunteers
- 242 people
- Sponsor
- Laboratoires Thea
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00864578
- Where
- Italy
- Sponsor
- Sooft Italia
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
- Trial name
- NCT05397600
- Testing
- Bimatoprost Ophthalmic
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 684 people
- Sponsor
- Laboratoires Thea
Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes
Clinical Study of the Optic Disc Parameters
Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, and Full Retinal Thickness between the Maestro and iVue OCT devices
- Conditions
- Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
- Trial name
- NCT02277119
- Testing
- Maestro, iVue
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Primary Open-Angle Glaucoma (POAG)
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma.
- Trial name
- NCT06903156
- Testing
- Mexidol
- Where
- 7 sites in Russia
- Volunteers
- 102 people
- Sponsor
- Pharmasoft
Primary Open-Angle Glaucoma (POAG)
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
- Trial name
- NCT06437639
- Testing
- Mexidol
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Pharmasoft
Glaucoma
Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of…
- Trial name
- T1030 (NCT01155219)
- Testing
- Geltim LP 1 mg/g, Xalatan
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Laboratoires Thea